Lead Product(s): ET-01
Therapeutic Area: Genetic Disease Product Name: ET-01
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 3H Health Investment
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 13, 2020
EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer. Proceeds from the financing will be used to advance the company’s pipeline into clinics.